Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Hawkey

Showing results (71-80 of 279) with videos related to

Pageof 28
Sort By:
BMJ (Clinical Research Ed.)|June 1, 2002
Potential alternatives to COX 2 inhibitorsM M Skelly, C J Hawkey
International Journal of Clinical Practice|June 13, 2003
COX-LOX inhibition: current evidence for an emerging new therapyM M Skelly, C J Hawkey
Bailliere'S Clinical Gastroenterology|June 1, 1994
Treatment of inflammatory bowel disease from now to the millenniumA T Cole, C J Hawkey
Autoimmunity|October 30, 2008
The role of stem cell transplantation in inflammatory bowel diseaseP J Fortun, C J Hawkey
Alimentary Pharmacology & Therapeutics|April 1, 1997
Review article: COX-II inhibitors--a new generation of safer NSAIDs?M T Donnelly, C J Hawkey
Drugs|August 1, 1989
Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapyA B Hawthorne, C J Hawkey
Digestive Diseases (Basel, Switzerland)|January 1, 1989
Aspirin and gastroduodenal injuryP J Prichard, C J Hawkey
Current Pharmaceutical Design|October 8, 2003
Dual COX inhibition and upper gastrointestinal damageM M Skelly, C J Hawkey
The American Journal of Medicine|February 13, 2001
Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statementC J Hawkey, A I Lanas,
Current Pharmaceutical Design|April 12, 2002
Gastrointestinal safety of selective COX-2 inhibitorsC J Hawkey, M M Skelly
Pageof 28

Showing results (71-80 of 279) with videos related to

Sort By:
Pageof 28
BMJ (Clinical Research Ed.)|June 1, 2002
Potential alternatives to COX 2 inhibitorsM M Skelly, C J Hawkey
International Journal of Clinical Practice|June 13, 2003
COX-LOX inhibition: current evidence for an emerging new therapyM M Skelly, C J Hawkey
Bailliere'S Clinical Gastroenterology|June 1, 1994
Treatment of inflammatory bowel disease from now to the millenniumA T Cole, C J Hawkey
Autoimmunity|October 30, 2008
The role of stem cell transplantation in inflammatory bowel diseaseP J Fortun, C J Hawkey
Alimentary Pharmacology & Therapeutics|April 1, 1997
Review article: COX-II inhibitors--a new generation of safer NSAIDs?M T Donnelly, C J Hawkey
Drugs|August 1, 1989
Immunosuppressive drugs in inflammatory bowel disease. A review of their mechanisms of efficacy and place in therapyA B Hawthorne, C J Hawkey
Digestive Diseases (Basel, Switzerland)|January 1, 1989
Aspirin and gastroduodenal injuryP J Prichard, C J Hawkey
Current Pharmaceutical Design|October 8, 2003
Dual COX inhibition and upper gastrointestinal damageM M Skelly, C J Hawkey
The American Journal of Medicine|February 13, 2001
Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statementC J Hawkey, A I Lanas,
Current Pharmaceutical Design|April 12, 2002
Gastrointestinal safety of selective COX-2 inhibitorsC J Hawkey, M M Skelly
Pageof 28